newsfilter
← Latest News
PR Newswire·

Triple-Gene Presented Preliminary Phase 1 Trial Data of Investigational Multigenic Therapeutic Candidate INXN‑4001 for Treatment of Heart Failure at American Heart Association Annual Meeting

Triple-Gene LLC, a clinical stage cardiovascular gene therapy company and majority owned subsidiary of Intrexon Corporation (NASDAQ: XON), yesterday...